Alendronic acid/pamidronic acid
- PDF / 135,074 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 65 Downloads / 235 Views
1
Alendronic acid/pamidronic acid Maternal hypocalcaemia, and hypocalcaemia in an infant following in utero exposure: 2 case reports A 30-year-old woman with osteogenesis imperfecta type 1 received oral alendronic acid 10 mg/day for 6 months, followed by IV pamidronic acid 90mg every 4 months for 1 year; she became pregnant 2 months after completing pamidronic acid therapy. She had an uneventful pregnancy, apart from hypocalcaemia at 8 weeks’ gestation. A healthy baby girl was delivered vaginally at 39 weeks’ gestation. At 2 months of age, the infant was found to have asymptomatic hypocalcaemia, which normalised by the age of 5 months. The mother developed hypocalcaemia at 3 months post-partum, but remained pain- and fracture-free 1 month later, and her bone mineral density was unchanged compared to before conception. Hassen-Zrour S, et al. Maternal and fetal outcome after long-term bisphosphonate exposure before conception. Osteoporosis International 21: 709-710, No. 4, Apr 2010. Available from: URL: http://dx.doi.org/10.1007/s00198-009-0983-1 803018849 Tunisia
0114-9954/10/1304-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 5 Jun 2010 No. 1304
Data Loading...
